Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Taselisib治疗PIK3CA突变实体瘤（乳腺癌和鳞状肺癌除外）的II期研究：NCI-MATCH ECOG-ACRIN试验（EAY131）子方案I的结果
期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO.21.00424
Krop, Ian E; Jegede, Opeyemi A; Grilley-Olson, Juneko E; Lauring, Josh D; Mitchell, Edith P; Zwiebel, James A; Gray, Robert J; Wang, Victoria; McShane, Lisa M; Rubinstein, Larry V; Patton, David; Williams, P Mickey; Hamilton, Stanley R; Kono, Scott A; Ford, James M; Garcia, Agustin A; Sui, Xingwei D; Siegel, Robert D; Slomovitz, Brian M; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T
